Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals develops oral antiviral therapeutics for serious viral diseases. The company uses a proprietary nucleos(t)ide prodrug platform focused on single-stranded RNA viruses and is building a pipeline that includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment.
Recurring Atea news covers clinical and preclinical antiviral development, including HCV Phase 3 studies such as C-BEYOND and C-FORWARD, hepatitis E virus candidates including AT-587 and AT-2490, scientific conference presentations, financial results, and business updates tied to pipeline execution.
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call on May 10, 2022, at 8:00 a.m. ET to share financial results for Q1 ended March 31, 2022, and provide a business update. Investors can access the call by dialing (800) 343-5172 domestically or (203) 518-9814 internationally, with conference ID AVIRQ122. A live audio webcast and slide presentation will be available on Atea's website.
Atea focuses on developing oral antiviral therapies for severe viral diseases, including COVID-19 and hepatitis C.
Atea Pharmaceuticals presented favorable nonclinical data for bemnifosbuvir (AT-527) at the SOT 61st Annual Meeting in San Diego. The company reported a nonclinical safety profile with no reproductive or developmental toxicity in animal models. This includes:
- No effects on fertility or reproduction in rats.
- No embryofetal abnormalities in rabbits at high doses.
- Low potential for QTc prolongation in both rats and monkeys.
CEO Jean-Pierre Sommadossi emphasized its suitability for clinical development against severe viral infections, including COVID-19 and hepatitis C.
Atea Pharmaceuticals (Nasdaq: AVIR) reported strong financial results for Q4 and the full year 2021, with collaboration revenue of $192.2 million and total revenue of $351.4 million, significantly up from $48.6 million in 2020. The net income was $117.1 million, compared to $20.7 million in the previous year. Atea is advancing three Phase 2 programs targeting COVID-19, hepatitis C, and dengue fever, and anticipates important milestones in 2022. With cash reserves of $764.4 million, the company is well-positioned to fund ongoing developments.
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on February 28, 2022, at 4:30 p.m. ET. This event will report the fourth-quarter and full-year financial results for 2021, and provide a business update. Atea, focused on developing oral therapies for severe viral diseases, aims to address unmet medical needs, particularly for infections like COVID-19 and hepatitis C. Following the live call, an archived version will be accessible on the company’s website.
Atea Pharmaceuticals has appointed Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development, enhancing its expertise in drug discovery and development. Dr. Agrawal, with over 25 years of experience at Merck, replaces Steven Good, who will retire this year. Her extensive background in developing antivirals aligns with Atea's mission to create oral therapies for severe viral diseases. The company is focused on expanding its pipeline, including treatments for COVID-19, hepatitis C, dengue, and RSV.
BOSTON, Feb. 09, 2022 – Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced that CEO Jean-Pierre Sommadossi and the management team will present a business update at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 2:20 p.m. ET. A live webcast of the event will be accessible on the company’s website, with a replay available for 90 days. Atea focuses on developing oral therapies for severe viral diseases, including SARS-CoV-2 and hepatitis C, utilizing a proprietary nucleotide prodrug platform.
Atea Pharmaceuticals has announced new findings published in Nature Communications regarding its antiviral drug bemnifosbuvir (AT-527). The data reveal that bemnifosbuvir's unique dual mechanism targets both chain termination and nucleotidylyltransferase inhibition, which may create a significant barrier to viral resistance. In Phase 2 trials, the drug has shown rapid antiviral activity and is generally safe for high-risk COVID-19 patients. This positions bemnifosbuvir as a promising option for treating COVID-19 and other viral diseases, according to Atea's leadership.
Atea Pharmaceuticals (AVIR) is advancing its clinical development strategy with plans for a global Phase 2 outpatient trial of bemnifosbuvir (AT-527) for COVID-19. The company has also secured exclusive worldwide rights to ruzasvir (RZR) from Merck, aiming to combine it with bemnifosbuvir for hepatitis C treatment. Furthermore, Atea is launching a Phase 2 proof-of-concept program for AT-752 targeting dengue fever. The Phase 2 COVID-19 trial will enroll 200 high-risk outpatients, with topline data expected in late 2022.
Atea Pharmaceuticals (Nasdaq: AVIR) announced that CEO and Founder Jean-Pierre Sommadossi will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 8:15 a.m. ET. A live webcast of the presentation will be available on the Company’s website and will remain accessible for 90 days post-event.
Atea focuses on developing oral therapies for life-threatening viral diseases, leveraging its expertise in antiviral drug development and nucleos(t)ide chemistry, targeting viruses like SARS-CoV-2 and hepatitis C.
Atea Pharmaceuticals (Nasdaq: AVIR) announced its inclusion in the NASDAQ Biotech Index, effective December 20, 2021. This addition aims to enhance the company's visibility in the investment community. CEO Jean Pierre Sommadossi emphasized that joining the index will broaden awareness of Atea's mission to develop oral antiviral treatments for severe viral diseases, including COVID-19. The NASDAQ Biotech Index tracks biotechnology and pharmaceutical securities that meet specific eligibility criteria, reinforcing Atea's standing in the biopharmaceutical sector.